70 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
. Dollars)
Three months ended
March 31
Note
Expenses
Research and development
Consulting, wages and benefits
Directors’ fees
Investor relations … to finance its research and development activities and its clinical studies. To achieve the objectives in its business plan, the Company plans to raise
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our … strategic partners is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
2)
Restated
(Note 2)
Expenses
Research and development
Wages and benefits
Consulting
Directors’ fees
Investor relations
Professional fees
General … clinical studies and their results. The Company will have to finance its research and development activities and its clinical studies. To achieve
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
in U.S. Dollars)
Three months ended
March 31
Note
Expenses
Research and development
Consulting, wages and benefits
Directors’ fees
Investor relations … to finance its research and development activities and its clinical studies. To achieve the objectives in its business plan, the Company plans to raise
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our … strategic partners is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize
424B3
zhb sdk148r5ys1v
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.1
n1pscyz0
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.2
irga cqyau75
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
424B5
ljzygy 5n3kg
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.1
mli2jh
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.2
p7kcz
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
moufz6d1poecmszhzbm
25 Aug 23
Prospectus supplement
6:00am
424B3
an4u19a
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
lpp gywo3hpdv7ed0t
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
6-K
EX-99.1
lt0ngj3
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
hh993pw805uxwn kz
14 Aug 23
Prospectus supplement
4:42pm
424B3
amk7rfn4r0s5ld18v
14 Aug 23
Prospectus supplement
4:40pm
POS AM
pdp9bcgnorf 3m
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm